Quantcast
Last updated on April 16, 2014 at 13:26 EDT

Latest JUPITER trial Stories

2010-04-27 01:00:00

LONDON, April 27 /PRNewswire/ -- CRESTOR(TM) (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk* of having a first cardiovascular event. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/astrazeneca/43661/ (Photo: http://www.newscom.com/cgi-bin/prnh/20100427/MM93313) This new indication is based on subgroup data from the landmark...

2010-04-20 09:51:00

Same gene involved in statins lowering cholesterol ANN ARBOR, Mich., April 20 /PRNewswire-USNewswire/ -- A genetic test can help determine in which patients cholesterol-lowering statin drugs might have the most benefit in also reducing the risk of colorectal cancer, a new study from researchers at the University of Michigan Comprehensive Cancer Center finds. The researchers had previously shown that statins - which 25 million people worldwide take each day to reduce their risk of...

2010-01-07 18:56:57

Gene variants associated with increased circulating levels of C-reactive protein, a marker of inflammation, are not associated with an increased risk of cancer, according to a new brief communication published online January 7 in the Journal of the National Cancer Institute. Stig E. Bojesen, M.D., Ph.D., of the Department of Clinical Biochemistry, Herlev Hospital, and Copenhagen University Hospital in Denmark, and colleagues used a Mendelian randomization design to test whether C-reactive...

2009-12-15 16:58:00

WILMINGTON, Del., Dec. 15 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR® (rosuvastatin calcium) in individuals meeting the following criteria: Men greater than or equal to 50 years, women greater than or equal to 60 years; Fasting LDL...

2009-11-16 07:00:00

Study highlights: - Risks of an anemia drug appear to outweigh its benefits among diabetic patients with kidney disease, anemia and a history of cardiovascular disease or stroke. - This first large, randomized, placebo-controlled trial finds drug raises hemoglobin levels and reverses anemia but does not improve patient cardiovascular outcomes. - Treatment with darbepoetin alfa in patients with type 2 diabetes, chronic kidney disease and moderate anemia doubled the risk of stroke compared...

a35ff5f768558b3a7d0f1b19e30e755c
2009-11-04 09:54:51

Searching for a needle in a haystack may seem futile, but it's worth it if the needle is a hard-to-detect protein that may identify a person at high risk of a heart attack circulating within a haystack of human serum (liquid component of blood). C-reactive protein (CRP), a molecule produced by the liver in response to inflammation, normally accounts for less than 1/60,000 of a person's total serum protein, or about 1 milligram per liter (mg/L) of serum. Recent evidence suggests that a CRP...

2009-10-19 17:49:51

People with high levels of a protein called C-reactive protein (CRP), a marker for inflammation in the blood, may be at higher risk for heart attack and death but not stroke, according to a study published in the October 20, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology. The study involved 2,240 people from the Northern Manhattan Study who were 40 years old or older and stroke-free. Of the group, 63 percent were Hispanic, 20...

2009-07-08 15:58:00

WASHINGTON, July 8 /PRNewswire-USNewswire/ -- The results of a study published in the current issue of the peer reviewed British Medical Journal (BMJ) support the findings of a white paper released last month by the Senior Center for Health and Security (SCHS) regarding the potentially lifesaving qualities of cholesterol lowering drugs known as statins. The report concluded, "In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was...

2009-07-08 08:00:00

WALTHAM, Mass., July 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the treatment of dyslipidemia patients who fail to reach LDL goal, surveyed physicians are increasingly switching patients to a more potent statin --- most notably AstraZeneca's Crestor --- rather than adding Merck/Schering-Plough's Zetia (ezetimibe) or switching to Merck/Schering-Plough's Vytorin (simvastatin/ezetimibe)....

2009-06-30 12:25:26

A non-profit senior health organization says the use of statins might significantly reduce the impact of cardiovascular disease in the United States. The Senior Center for Health and Security has released a white paper saying the adverse health and financial impact of cardiovascular disease -- the number one killer of men and women in the United States -- can be significantly reduced through the well monitored use of statins. The paper explores the ramifications of heart disease and stroke,...